CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.

Xuehui WuXiaoliang LanWanming HuWanning ZhangXiangmeng LaiShaowan XuJiaoying LiWeihao QiuWei WangJianbiao XiaoFeifei WangYanqing DingLi Liang

Published in: Cancer immunology, immunotherapy : CII (2021)

CMTM6 expression in M2 macrophages may predict the PD-1/PD-L1 inhibitor response rate in CRC patients more accurately than dMMR/microsatellite instability-high (MSI-H) status. It can also identify pMMR CRC patients who could benefit from PD-1/PD-L1 inhibitors.

Keyphrases

poor prognosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
binding protein
prognostic factors
peritoneal dialysis
long non coding rna
risk assessment